Abstract
Our Research Regarding Neurorehabilitation Outcomes of The Treatment with Calf Blood Deproteinized Medicine (Actovegin®) in Subacute/Subchronic Stages of Ischemic Stroke Patients – Preliminary Results
Highlights
The central nervous system (CNS) illness are major sources of burden to both patients and caregivers, that severely affect the quality of life of patients [1], entailing huge individual and community expenses, with tremendous family, social and labour implications, at the same time
The outcome specific scores showed for the Actovegin® group, compared to the control group, a superior mean in FIMt and FIMm, highly significant (p < 0.001) and in percentages, significantlly on GOS 95% CI 27.28% to 68.34%; the number needed to treat – NNT – was 2.1, and respectively on mR(D)S 95% CI 57.19% to 89.68% and NNT was 1.4
There weren’t observed statistically significant differences between discharge and admission, on FIMc and MMSE scales and respectively, on standard biological parameters of the inflammatory syndrome. It has been observed the highest level of mean efficiency of Actovegin® on the Barthel Index and the lowest one on the IADL
Summary
The central nervous system (CNS) illness are major sources of burden to both patients and caregivers, that severely affect the quality of life of patients [1], entailing huge individual and community expenses, with tremendous family, social and labour implications, at the same time In this panel diseases, stroke is mentioned as a leader in incidence, as well as a medical and economic matter [2]. Stroke is a major worldwide public health issue no matter if are hight, middle or low incoming countries, but there are significant differences, for instance, among Eastern and Western European countries From this perspective, Romania held (in 2015) an unwanted leading position among the EU countries as numbers of stroke new cases and deaths by stroke, as well [4,6]. The medicine Actovegin® is considered to have many beneficial effects scarcely studied in ischemic stroke
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
